Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy
Jielin Liu(The University of Texas MD Anderson Cancer Center), Padmanee Sharma(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
|Nature Communications|2021|60